[PDF][PDF] Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain

ND Volkow, GJ Wang, JS Fowler, J Logan… - The Journal of …, 2001 - Soc Neuroscience
ND Volkow, GJ Wang, JS Fowler, J Logan, M Gerasimov, L Maynard, YS Ding, SJ Gatley
The Journal of Neuroscience, 2001Soc Neuroscience
Methylphenidate (Ritalin) is the most commonly prescribed psychoactive drug in children for
the treatment of attention deficit hyperactivity disorder (ADHD), yet the mechanisms
responsible for its therapeutic effects are poorly understood. Whereas methylphenidate
blocks the dopamine transporter (main mechanism for removal of extracellular dopamine), it
is unclear whether at doses used therapeutically it significantly changes extracellular
dopamine (DA) concentration. Here we used positron emission tomography and [11C] …
Methylphenidate (Ritalin) is the most commonly prescribed psychoactive drug in children for the treatment of attention deficit hyperactivity disorder (ADHD), yet the mechanisms responsible for its therapeutic effects are poorly understood. Whereas methylphenidate blocks the dopamine transporter (main mechanism for removal of extracellular dopamine), it is unclear whether at doses used therapeutically it significantly changes extracellular dopamine (DA) concentration. Here we used positron emission tomography and [11C] raclopride (D2 receptor radioligand that competes with endogenous DA for binding to the receptor) to evaluate whether oral methylphenidate changes extracellular DA in the human brain in 11 healthy controls. We showed that oral methylphenidate (average dose 0.8 0.11 mg/kg) significantly increased extracellular DA in brain, as evidenced by a significant reduction in Bmax/Kd (measure of D2 receptor availability) in striatum (20 12%; p 0.0005). These results provide direct evidence that oral methylphenidate at doses within the therapeutic range significantly increases extracellular DA in human brain. This result coupled with recent findings of increased dopamine transporters in ADHD patients (which is expected to result in reductions in extracellular DA) provides a mechanistic framework for the therapeutic efficacy of methylphenidate. The increase in DA caused by the blockade of dopamine transporters by methylphenidate predominantly reflects an amplification of spontaneously released DA, which in turn is responsive to environmental stimulation. Because DA decreases background firing rates and increases signal-to-noise in target neurons, we postulate that the amplification of weak DA signals in subjects with ADHD by methylphenidate would enhance task-specific signaling, improving attention and decreasing distractibility. Alternatively methylphenidate-induced increases in DA, a neurotransmitter involved with motivation and reward, could enhance the salience of the task facilitating the “interest that it elicits” and thus improving performance.
Soc Neuroscience